Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 30, 2011

Poll Respondents Mostly Confident U.S. Can Protect Second-Opinion Genetic Test Developers

  • A GEN poll reveals that people mostly believe that the U.S. can develop a system to protect innovator diagnostic firms as well as safeguard those offering confirming tests against patent infringement. Some two-thirds of respondents (66.7%) expressed such confidence, while the remainder (33.3%) was undecided, and no respondents disagreed.

    The U.S. Patent & Trademark Office (USPTO) faces a June 16 deadline for submitting to Congress a study on “effective ways to provide independent, confirming genetic diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic tests exist.” USPTO is expected to take its first step toward such recommendations in mid-January, when it is to announce dates and places for hearings on confirming genetic diagnostic tests. Advocates for such testing say the current system based on patent eligibility drives up costs, limits patient options, reduces innovation, and harms medical practice. Diagnostic developers counter that patent eligibility provides the financial incentives that allow them to recoup the costs of developing the tests


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »